Thousands of UK patients are set to take part in the world’s first mRNA cancer vaccine trials, expedited by the NHS. These vaccines will be personalized, tailored to each individual’s DNA. The initial focus will be on bladder, colorectal, kidney, lung, skin, and pancreatic cancers, with plans to expand to other types in the future.
Read more: Indian Actress With Stage 3 Breast Cancer Rushed From Awards Show To Hospital
Eligible patients will need to provide blood and tissue samples to participate. The program, known as the Cancer Vaccine Launch Pad, encompasses 30 UK sites and involves a collaboration with BioNTech. The first participant, Elliot Pfebve, who has colorectal cancer, has already received the vaccine. While early results are promising, further data is required to assess the vaccine’s effectiveness.
